AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-03. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
== Refusal == In the United States federal criminal system, refusing to take a drug test triggers an automatic revocation of probation or supervised release. In Victoria, Australia the driver of the car has the option to refuse the drug test. Refusing to undergo a drug test or refusing to undergo a secondary drug test after the first one, triggers an automatic suspension and disqualification for a period of two years and a fine of AUD$1000. The second refusal triggers an automatic suspension and disqualification for a period of four years and an even larger fine.
Half-Life: Hostile Takeover: an expansion pack for the original Half-Life developed by 2015, reportedly cancelled in 2000. Half-Life 2: Episode Three: announced in 2006 with a release date of late 2007, and then put on hold, possibly cancelled due to scope creep, unsatisfactory internal experiments, and the desire to develop the Source 2 engine first. Untitled Half-Life 2 episode: developed by Junction Point Studios and led by Warren Spector. Development ceased when Junction Point signed a deal with Disney Interactive Studios to develop Epic Mickey. Valve took Junction Point's project and passed it to Arkane Studios. Ravenholm (also known as Return to Ravenholm or Half-Life 2: Episode Four): developed by Arkane Studios around 2006–2007, with Opposing Force protagonist Adrian Shephard as the player character and Father Grigori from Half-Life 2 in a supporting role. Half-Life 3: a version of Half-Life 3 was in development on the Source 2 engine from 2013 to 2014. Valve planned to incorporate procedurally generated levels alongside a "crafted experience" so that no two playthroughs of the game would be identical. It was cancelled as Source 2 was not yet stable enough to support full-scale development. Borealis: a virtual reality game led by writer Marc Laidlaw in development in 2015, set aboard the time-travelling ship Borealis. It was cancelled as it failed to gain momentum.
In the event wealthy landowners, members of the nascent agrarian bourgeoisie in search of social status, bought the best land. Ferdinand's reforms ended shortly after the French Revolution. Revolutionary ideas were spreading across continental Europe thanks to the invasion of French revolutionary armies, alarming the courts of the Old Regime. Ferdinand IV in 1supported joined the anti-French coalition and marched with his army to Rome, where Pope Pius VI had been deposed and the Roman Republic proclaimed. The Bourbon army had to retreat after initial successes, pursued by French troops supporting the Italian Jacobin revolutionaries. It moved from Naples to Sicily, while on 21 January 1799, the Parthenopean Republic was proclaimed. Its formation document was drafted by the Calabrian Jacobin Giuseppe Logoteta.
=== GLP-1 weight loss entry and Super Bowl advertising (2024–2025) === In May 2024, Hims & Hers began offering access to compounded injectable semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1) prescription treatment, as part of a new weight-loss specialty on its platform. The move followed a national shortage of branded semaglutide products Ozempic and Wegovy made by Novo Nordisk, which allowed Section 503A compounding pharmacies and 503B outsourcing facilities to legally produce copies of the drug. In September 2024, the company acquired MedisourceRx, a licensed 503B compounding outsourcing facility, to vertically integrate its compounded medicine supply chain. In February 2025, Hims & Hers aired a 60-second commercial titled "Sick of the System" during Super Bowl LIX on Fox, the first Super Bowl advertisement to promote GLP-1 weight loss treatments. The advertisement drew criticism from public health experts, industry trade groups and members of the United States Congress for framing the compounded semaglutide products as a solution to the American obesity epidemic without disclosing side-effect or risk information. Senators Dick Durbin and Roger Marshall wrote a joint letter to the Food and Drug Administration urging enforcement action.
== Toxicological experiments == During the 1980s the Philip Morris Tobacco Company carried out research on sidestream smoke at the Institut für Biologische Forschung, although this was not voluntarily published. This study found that sidestream smoke is nearly four times more toxic than mainstream smoke per metric gramme. They also found that sidestream condensate was nearly three times more toxic than mainstream smoke as well as 2–6 times more tumourigenic per gram than mainstream condensate when applied to the skin of a mouse; results also showed that sidestream smoke hinders an animal's ability to reach a weight that is considered normal. The research team concluded that the only way to protect oneself from sidestream smoke was to be in smoke-free public places and workspaces.
Sources: en.wikipedia.org
=== China === Castillo has sought to improve relations with China. The Castillo Administration sees China as an essential trade partner, and as a partner for vaccine procurement. China is the main buyer of Peru's copper, a crucial source of the country's tax revenue. In the first week of Castillo's government, cabinet members met with Liang Yu, China's ambassador to Peru, and executives from major mining companies from the Asian country, following campaign announcements in which Castillo announced higher mining taxes and the review of tax stability agreements signed with transnational corporations, which caused concern among Chinese companies. Following a meeting between Yu and Roberto Sánchez, minister of foreign trade and tourism, it was announced that, virtually, technical teams from Peru and China were working on the "optimization of the FTA between both countries". Subsequently, in February 2022, lobbyist Karelim López testified before prosecutors about the existence of an alleged mafia within the Ministry of Transport and Communications (MTC) that was led by Castillo and Juan Silva, minister of the MTC, and included the congressmen known as "Los Niños" in order to steer public works in exchange for favors.
The side effects of photodynamic therapy can be divided into onset side effects, which occur which early exposure to light. Early onset side effects of photodynamic Therapy (PDT) commonly include pain and Local Skin Reactions (LSRs), such as erythema, Edema, desquamation, and pustulae. These effects are frequently observed during or shortly after exposure to the light source used in PDT and may occur in combination. Less common side effects include urticaria, contact dermatitis, and erosive pustular dermatosis of the scalp (EPDS). Additionally, PDT can have an acute impact on the immune system, which, although immediate in onset, may have long-term implications for treatment-related changes in carcinogenesis. Late onset side effects, include pigmentary changes and scarring, affecting approximately 0.8% of patients. There is also a risk of developing bullous pemphigoid, and there is potential for PDT to induce or stimulate skin carcinogenesis.
Freezing food preserves it from the time it is prepared to the time it is eaten. Since early times, farmers, fishermen, and trappers have preserved grains and produce in unheated buildings during the winter season. Freezing food slows decomposition by turning residual moisture into ice, inhibiting the growth of most bacterial species. In the food commodity industry, there are two processes: mechanical and cryogenic (or flash freezing). The freezing kinetics is important to preserve the food quality and texture. Quicker freezing generates smaller ice crystals and maintains cellular structure. Cryogenic freezing is the quickest freezing technology available due to the ultra low liquid nitrogen temperature −196 °C (−320 °F). Preserving food in domestic kitchens during modern times is achieved using household freezers. Accepted advice to householders was to freeze food on the day of purchase. An initiative by a supermarket group in 2012 (backed by the United Kingdom's Waste & Resources Action Programme) promotes the freezing of food "as soon as possible up to the product's 'use by' date". The Food Standards Agency was reported as supporting the change, provided the food had been stored correctly up to that time.
A simple reciprocating pump is commonly made up of a cylinder with an inlet, an outlet, and a piston within. The inlet and the outlet are used to direct the flow of air, while the piston is used to generate the flow of air. When the piston is pulled up, air gets sucked into the pump through the inlet. The pump chamber depressurizes as it fills with air. When the piston is forced down, the air becomes compressed and closes the inlet. Then the air flows out from the outlet. Rotary Vane Pump
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.